A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
Braz. j. infect. dis
;
15(5): 498-500, Sept.-Oct. 2011.
Article
in English
| LILACS
| ID: lil-612714
ABSTRACT
Darunavir (DRV) is an HIV-1 protease inhibitor that is used together with a low boosting dose of ritonavir as part of an antiretroviral therapy (ART) regimen in treatment-experienced and naïve HIVpositive patients. In naïve and experienced patients with no DRV-mutations, DRV is licensed at the dose of 800 mg plus 100 mg of ritonavir once daily. We report our results in seven ART-experienced HIV-infected patients, in whom a reduced dose of darunavir/ritonavir (600/100 mg once daily) successfully controlled viral replication.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Sulfonamides
/
HIV Infections
/
HIV Protease Inhibitors
/
Ritonavir
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
English
Journal:
Braz. j. infect. dis
Journal subject:
Communicable Diseases
Year:
2011
Type:
Article
Affiliation country:
Botswana
/
Italy
Institution/Affiliation country:
G.B. Rossi Hospital/IT
/
University of Botswana/BW
/
University of Torino/IT
Similar
MEDLINE
...
LILACS
LIS